IBRN - ETF AI Analysis

Top Page

iShares Neuroscience and Healthcare ETF (IBRN)

Rating:53Neutral

Price Target:―

The iShares Neuroscience and Healthcare ETF (IBRN) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Catalyst Pharma stands out as a key contributor, driven by strong revenue growth, profitability, and attractive valuation metrics. On the other hand, weaker holdings like Centessa Pharmaceuticals, which faces significant financial challenges and bearish technical indicators, may have weighed down the fund's rating. A notable risk factor is the ETF's exposure to companies with high financial leverage and ongoing losses, which could impact its long-term stability.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid returns year-to-date, indicating strong momentum in its holdings.

Focused Healthcare Exposure

With over 91% of assets in healthcare, the fund targets a high-growth sector with long-term potential.

Reasonable Expense Ratio

The ETF charges a moderate fee compared to many specialized funds, making it cost-effective for investors.

Negative Factors

Over-Concentration in Healthcare

The fund's heavy focus on healthcare limits diversification and exposes investors to sector-specific risks.

Underperforming Holdings

Several top holdings, including Biogen and Catalyst Pharma, have shown weak or negative performance recently.

Limited International Exposure

With over 81% of assets in U.S. companies, the ETF offers minimal diversification across global markets.

IBRN vs. SPDR S&P 500 ETF (SPY)

AUM4.89M

RegionGlobal

Expense Ratio0.47%

Beta1.12

IssueriShares

Inception DateAug 24, 2022

Dividend Yield0.31%

Asset ClassEquity

Index TrackedNYSE FactSet Global Neuro Biopharma and MedTech Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume1,237

30 Day Avg. Volume957

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

44.77

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering58

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IBRN Summary

The iShares Neuroscience and Healthcare ETF (IBRN) is a fund that focuses on companies in the health care sector, particularly those working on cutting-edge neuroscience, pharmaceuticals, and biotechnology. It tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, giving investors exposure to innovative firms like Biogen and Catalyst Pharma, which are leaders in neurological treatments. This ETF could be appealing for someone looking to invest in medical advancements and diversify their portfolio with health care stocks. However, new investors should know that the fund’s performance is closely tied to the health care sector, which can be volatile and sensitive to regulatory changes.

How much will it cost me?The iShares Neuroscience and Healthcare ETF (IBRN) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to target specific companies in the neuroscience and healthcare fields.

What would affect this ETF?The iShares Neuroscience and Healthcare ETF (IBRN) could benefit from growing global demand for advanced neurological treatments and breakthroughs in biotechnology, as well as increased funding for health care innovation. However, it may face challenges from regulatory hurdles in drug approvals, potential economic slowdowns impacting research budgets, and competition within the pharmaceutical and biotech sectors. Its global exposure and focus on cutting-edge companies provide opportunities but also expose it to risks tied to international market conditions.

IBRN Top 10 Holdings

The iShares Neuroscience and Healthcare ETF (IBRN) is heavily concentrated in the health care sector, with a global mix of companies driving innovation in neuroscience and life sciences. Biogen and Axsome Therapeutics are steady performers, benefiting from strong revenue growth and strategic R&D efforts, though profitability concerns linger. Scholar Rock and Praxis Precision Medicines are lagging, weighed down by financial challenges and ongoing losses, despite promising pipelines. Meanwhile, Centessa Pharmaceuticals shows mixed signals, with recent gains offset by funding concerns. Overall, the fund’s focus on cutting-edge biotech and pharma creates both opportunities and risks for investors.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
PRAX	Praxis Precision Medicines	7.25%	$353.88K	$6.72B	276.45%	58 Neutral
SRRK	Scholar Rock Holding	4.74%	$231.43K	$4.78B	11.65%	50 Neutral
PTCT	PTC Therapeutics	4.19%	$204.44K	$6.07B	63.12%	72 Outperform
BIIB	Biogen	3.90%	$190.44K	$25.54B	16.04%	74 Outperform
AXSM	Axsome Therapeutics	3.78%	$184.60K	$7.47B	64.45%	57 Neutral
ARGX	Argenx Se	3.77%	$184.12K	$54.47B	44.59%	79 Outperform
XENE	Xenon	3.54%	$172.89K	$3.40B	10.01%	48 Neutral
CPRX	Catalyst Pharma	3.52%	$171.71K	$2.90B	10.48%	83 Outperform
NBIX	Neurocrine	3.41%	$166.67K	$15.24B	20.60%	80 Outperform
ACAD	ACADIA Pharmaceuticals	3.36%	$163.95K	$4.59B	57.30%	75 Outperform

IBRN Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

29.72

Positive

100DMA

27.31

Positive

200DMA

24.83

Positive

Market Momentum

MACD

0.96

Negative

RSI

64.24

Neutral

STOCH

76.35

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.13, equal to the 50-day MA of 29.72, and equal to the 200-day MA of 24.83, indicating a bullish trend. The MACD of 0.96 indicates Negative momentum. The RSI at 64.24 is Neutral, neither overbought nor oversold. The STOCH value of 76.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRN.

IBRN Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IBRN	―	―	$4.89M	0.47%	―
FMED	―	―	$64.79M	0.50%	―
HTEC	―	―	$53.22M	0.68%	―
HRTS	―	―	$52.30M	0.75%	―
OZEM	―	―	$44.40M	0.59%	―
PSIL	―	―	$19.64M	1.00%	―

Performance Comparison

IBRN

iShares Neuroscience and Healthcare ETF

32.52

6.15

23.32%

FMED

Fidelity Disruptive Medicine ETF

―

HTEC

ROBO Global Healthcare Technology and Innovation ETF

―

HRTS

Tema Cardiovascular and Metabolic ETF

―

OZEM

Roundhill GLP-1 & Weight Loss ETF

―

PSIL

AdvisorShares Psychedelics ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents